Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,703.50
Bid: 1,703.00
Ask: 1,703.50
Change: -1.50 (-0.09%)
Spread: 0.50 (0.029%)
Open: 1,705.00
High: 1,711.00
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Big Pharma's bet on Big Data creates opportunities and risks

Tue, 26th Jan 2016 13:07

* Novartis plans to sell cloud-connected inhaler by 2019

* Part of companies' push into "Medical Internet of Things"

* Pharma and tech firms teaming up in hunt for Big Data

* But web-enabled devices present privacy and security risks

By John Miller

ZURICH, Jan 26 (Reuters) - Novartis wants everypuff of its emphysema drug Onbrez to go into the cloud.

The Swiss drugmaker has teamed up with U.S. technology firmQualcomm to develop an internet-connected inhaler thatcan send information about how often it is used to remotecomputer servers known as the cloud.

This kind of new medical technology is designed to allowpatients to keep track of their drug usage on their smartphonesor tablets and for their doctors to instantly access the dataover the web to monitor their condition.

It also creates a host of "Big Data" opportunities for thecompanies involved - with huge amounts of information about amedical condition and the efficacy of a drug or device beingwirelessly transmitted to a database from potentially thousands,even millions, of patients.

The potential scale of the so-called "Medical Internet ofThings" has not been lost on pharmaceutical and tech firmsaround the world, both big companies hunting growth and smallerones looking to provide bespoke products and services.

It has created unlikely alliances.

Novartis' domestic rival Roche has also teamed upwith Qualcomm and Danish diabetes drugmaker Novo Nordisk has partnered with IBM on cloud-linked deviceprojects, for example, while healthcare device maker Medtronic is working with a U.S. data-analytics firm Glooko.

GlaxoSmithKline, meanwhile, is in talks withQualcomm about a medical technology joint venture potentiallyworth up to $1 billion, according to people familiar with thematter.

However, with the opportunity comes risk.

Security experts warn that hacked medical information can beworth more than credit card details on the black market asfraudsters can use it to fake IDs to buy medical equipment ordrugs that can be resold, or file bogus insurance claims.

The U.S. Centers for Disease Control and Preventionestimates there are 35 million U.S. hospital discharges a year,a billion doctor and hospital visits and even moreprescriptions, much of which is stored in cloud databases.

CLOUD CONCERN

Now the "Medical Internet of Things" is introducing more andmore web-connected devices into the equation and pushing evenmore confidential patient data on to the cloud.

This is creating potential new opportunities for thievesseeking to penetrate medical companies' security where they maytarget names, birth dates, policy numbers, billing data and thediagnosis codes needed to obtain drugs, say experts.

"The weakest link tends to be the medical device itself,"said Rick Valencia, senior vice president of Qualcomm Life,Qualcomm's four-year-old healthcare unit. "They weren't designedwith the idea in mind that they would be going over the networkand the information would be residing in cloud infrastructure."

Medtronic, the world's largest standalone medical devicemaker, said in 2014 it lost patient records in separatecyberattacks at its diabetes business.

"The more information, the easier identity theft is and themore valuable the profiles that the hacker can sell to thirdparties," said Erik Vollebregt, a lawyer in Amsterdam whospecialises in medical device cybersecurity and privacy.

He said it could also be possible for criminals to hack intoweb-connected medical devices, and threaten the lives ofpatients, to blackmail the manufacturer.

Despite no documented patient-endangering hacks, the U.S.Food and Drug Administration warned last year an infusion pumpcould be vulnerable to attack and asked healthcare providers tostop using it.

SMART LENS

Novartis aims to have its inhaler for chronic lung disease,to be on the market by 2019. Other pharma-tech alliances includeAerocrine and Microsoft, which are workingtogether on a cloud project to analyse data from allergy andasthma patients.

Google is, meanwhile, working with Frenchdrugmaker Sanofi to collect and analyse informationfrom diabetes sufferers. The U.S. tech giant alsohas a partnership with Novartis to develop a smart contact lensthat can monitor diabetics' glucose levels.

All the companies involved in such projects say they aregoing to extreme lengths to protect patients' data from hackers.

Philips has turned to San Francisco-basedidentity-management software maker ForgeRock to keep data fromthe Dutch company's medical devices from falling into the wronghands.

Software security expert Marie Moe, of Norway's SINTEFscientific research foundation, said the wireless ports in thepacemaker that keeps her heart beating left it vulnerable tointrusion - but that she could not survive without the device.

"Wireless interfaces are a great benefit to certain patientgroups," she told Reuters. "But as a security researcher, I knowconnectivity also means vulnerability." (Additional reporting by Julie Steenhuysen in Chicago, JimFinkle in Boston and Ben Hirschler in London; Editing by PravinChar)

More News
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.